By the way, doctor: Tamoxifen versus aromatase inhibitors
Q. I've had an ER-positive breast cancer tumor removed. Now I am getting ready for follow-up therapy. I've heard that the aromatase inhibitors are better than tamoxifen. What is your opinion?
A. Breast cancer is classified according to whether it has receptors for the female hormone estrogen. If the cancer has estrogen receptors — or, as cancer specialists say, it is estrogen-receptor (ER) positive — estrogen can stimulate the cells to grow and divide, resulting in more cancer. About two-thirds of all breast cancers are ER-positive. The good news is that ER-positive tumors tend to be less aggressive than those that are ER-negative, so the prognosis tends to be quite a bit better. Still, blunting the effects of estrogen is important for preventing recurrence.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
